Loading patent…
AssigneeAstraZeneca AB
InventorsWitte Koopmann, Simon Smith
Estimating the term…
The present invention relates to the discovery of an association between the gene encoding FGF-BP1 (fibroblast growth factor-binding protein) and chronic obstructive pulmonary disease (COPD). The invention identifies a role for FGF-BP1 in COPD. The present invention therefore relates to diagnostic techniques for the detection of COPD by detecting all or part of this gene, its precursors or products (mRNA, cDNA, genomic DNA, or protein). The present invention also provides methods and as-says for identifying compounds which modulate FGF-BP1 and which may be used for treating respiratory diseases such as COPD. Furthermore, the invention relates to polymorphisms in the genes encoding FGF-BP1. The invention also relates to the use of polymorphisms in the FGF-BP1-encoding genes in assessing predisposition and/or susceptibility of an individual to chronic obstructive pulmonary disease (COPD).
A method for assessing the predisposition and/or susceptibility of an individual to COPD, which method comprises
A method for assessing the predisposition and/or susceptibility of an individual to COPD, which method comprises:
A method of treating an individual having, or at risk of having, COPD, with a drug capable of modulating FGF-BP1, which method comprises:
Use of a compound capable of modulating FGF-B1 expression or functional activity in the preparation of a medicament for treating COPD.
Use of a compound capable modulating FGF-BP1 expression or functional activity in the preparation of a medicament for treating an individual for COPD, wherein the individual has been identified as having a polymorphic nucleotide or a polymorphic nucleotide sequence which is associated with COPD in the FGF-BP1 gene.
Use of a drug capable of treating COPD in the preparation of a medicament medicament for treating an individual for COPD, wherein the individual has been identified as having a polymorphic nucleotide or a polymorphic nucleotide sequence which is associated with COPD in the FGF-BP1 gene.
A method of screening for a compound which can be used to treat COPD, which method comprises:
Dependencies are inferred from the claim text.